Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study
Background/Aims Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of ente...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Association of Internal Medicine
2019-01-01
|
Series: | The Korean Journal of Internal Medicine |
Subjects: | |
Online Access: | http://www.kjim.org/upload/pdf/kjim-2017-002.pdf |
id |
doaj-fd8e3d07ac304535b10bd246e002ee21 |
---|---|
record_format |
Article |
spelling |
doaj-fd8e3d07ac304535b10bd246e002ee212021-08-09T23:58:05ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482019-01-01341909810.3904/kjim.2017.002169968Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort studySeng Chan You0Hojun Park1Dukyong Yoon2Sooyoung Park3Boyoung Joung4Rae Woong Park5 Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea Department of Statistics, Ewha Womans University, Seoul, Korea Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea Department of Statistics, Ewha Womans University, Seoul, Korea Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, KoreaBackground/Aims Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of enteropathy in Korea. Methods Our retrospective cohort study used data from the Korean National Health Insurance Service to identify 108,559 patients (58,186 females) who were initiated on angiotensin converting enzyme inhibitors (ACEis), olmesartan, or other ARBs between January 2005 and December 2012. The incidences of enteropathy were compared among drug groups. Changes in body weight were compared after propensity score matching of patients in the ACEis and olmesartan groups. Results Among 108,559 patients, 31 patients were diagnosed with enteropathy. The incidences were 0.73, 0.24, and 0.37 per 1,000 persons, in the ACEis, olmesartan, and other ARBs groups, respectively. Adjusted rate ratios for enteropathy were: olmesartan, 0.33 (95% confidential interval [CI], 0.10 to 1.09; p = 0.070) and other ARBs, 0.34 (95% CI, 0.14 to 0.83; p = 0.017) compared to the ACEis group after adjustment for age, sex, income level, and various comorbidities. The post hoc analysis with matched cohorts revealed that the proportion of patients with significant weight loss did not differ between the ACEis and olmesartan groups. Conclusions Olmesartan was not associated with intestinal malabsorption or significant body weight loss in the general Korean population. Additional large-scale prospective studies of the relationship between olmesartan and the incidence of enteropathy in the Asian population are needed.http://www.kjim.org/upload/pdf/kjim-2017-002.pdfangiotensin receptor antagonistsolmesartaninsurance claim reviewdrug-related side effects and adverse reactionsintestinal diseases |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Seng Chan You Hojun Park Dukyong Yoon Sooyoung Park Boyoung Joung Rae Woong Park |
spellingShingle |
Seng Chan You Hojun Park Dukyong Yoon Sooyoung Park Boyoung Joung Rae Woong Park Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study The Korean Journal of Internal Medicine angiotensin receptor antagonists olmesartan insurance claim review drug-related side effects and adverse reactions intestinal diseases |
author_facet |
Seng Chan You Hojun Park Dukyong Yoon Sooyoung Park Boyoung Joung Rae Woong Park |
author_sort |
Seng Chan You |
title |
Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study |
title_short |
Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study |
title_full |
Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study |
title_fullStr |
Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study |
title_full_unstemmed |
Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study |
title_sort |
olmesartan is not associated with the risk of enteropathy: a korean nationwide observational cohort study |
publisher |
The Korean Association of Internal Medicine |
series |
The Korean Journal of Internal Medicine |
issn |
1226-3303 2005-6648 |
publishDate |
2019-01-01 |
description |
Background/Aims Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of enteropathy in Korea. Methods Our retrospective cohort study used data from the Korean National Health Insurance Service to identify 108,559 patients (58,186 females) who were initiated on angiotensin converting enzyme inhibitors (ACEis), olmesartan, or other ARBs between January 2005 and December 2012. The incidences of enteropathy were compared among drug groups. Changes in body weight were compared after propensity score matching of patients in the ACEis and olmesartan groups. Results Among 108,559 patients, 31 patients were diagnosed with enteropathy. The incidences were 0.73, 0.24, and 0.37 per 1,000 persons, in the ACEis, olmesartan, and other ARBs groups, respectively. Adjusted rate ratios for enteropathy were: olmesartan, 0.33 (95% confidential interval [CI], 0.10 to 1.09; p = 0.070) and other ARBs, 0.34 (95% CI, 0.14 to 0.83; p = 0.017) compared to the ACEis group after adjustment for age, sex, income level, and various comorbidities. The post hoc analysis with matched cohorts revealed that the proportion of patients with significant weight loss did not differ between the ACEis and olmesartan groups. Conclusions Olmesartan was not associated with intestinal malabsorption or significant body weight loss in the general Korean population. Additional large-scale prospective studies of the relationship between olmesartan and the incidence of enteropathy in the Asian population are needed. |
topic |
angiotensin receptor antagonists olmesartan insurance claim review drug-related side effects and adverse reactions intestinal diseases |
url |
http://www.kjim.org/upload/pdf/kjim-2017-002.pdf |
work_keys_str_mv |
AT sengchanyou olmesartanisnotassociatedwiththeriskofenteropathyakoreannationwideobservationalcohortstudy AT hojunpark olmesartanisnotassociatedwiththeriskofenteropathyakoreannationwideobservationalcohortstudy AT dukyongyoon olmesartanisnotassociatedwiththeriskofenteropathyakoreannationwideobservationalcohortstudy AT sooyoungpark olmesartanisnotassociatedwiththeriskofenteropathyakoreannationwideobservationalcohortstudy AT boyoungjoung olmesartanisnotassociatedwiththeriskofenteropathyakoreannationwideobservationalcohortstudy AT raewoongpark olmesartanisnotassociatedwiththeriskofenteropathyakoreannationwideobservationalcohortstudy |
_version_ |
1721213161043918848 |